Adenovirus-Mediated Thymidine Kinase Gene Therapy for Recurrent Ovarian Cancer: Expression of Coxsackie-Adenovirus Receptor and Integrins αvβ3 and αvβ5

Objective: Ten patients with recurrent ovarian cancer received a combined treatment of optimal tumor debulking, adenovirus-mediated herpes simplex virus thymidine kinase gene therapy (GT), and systemic application of acyclovir or valacyclovir and topotecan. Biopsies were taken at the time of secondary debulking about 1 month after the application of GT and chemotherapy and were analyzed for expression of coxsackie-adenovirus receptor (CAR) and integrins αvβ3 and αvβ5 with respect to treatment response. Methods: Treatment modalities and study design have been described recently. Immunohistochemistry was used to visualize expression of CAR and integrins αvβ3 and αvβ5 in tumor samples taken before and after application of GT. Results: Before GT six of ten patients presented with CAR-positive and four with CAR-negative tumors. After GT all tumors showed CAR expression. Integrin αvβ3 was found in all tumors before and after GT. Expression of integrin αvβ5 was seen in eight of ten tumor samples before GT and in all samples after GT. Conclusion: Despite the importance of CAR and integrin expression for successful adenovirus internalization, other cell surface receptors might be involved in this process. It is too early to decide whether expressions of CAR and integrin αvβ3/αvβ5 on tumor cells are appropriate additional inclusion criteria for the enrollment of patients in GT trials. Further research is necessary to evaluate the effect of GT plus chemotherapy on CAR and integrin expression.

[1]  M. Chilosi,et al.  Heparan Sulfate Glycosaminoglycans Are Receptors Sufficient To Mediate the Initial Binding of Adenovirus Types 2 and 5 , 2001, Journal of Virology.

[2]  E. Venkatraman,et al.  Identification of prognostic factors in advanced epithelial ovarian carcinoma. , 2001, Gynecologic oncology.

[3]  P. Leung,et al.  Ovarian surface epithelium: biology, endocrinology, and pathology. , 2001, Endocrine reviews.

[4]  A. Hasenburg,et al.  Coxsackievirus–adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression , 2001, Cancer Gene Therapy.

[5]  D. Curiel,et al.  Adenoviral-mediated suicide gene therapy for ovarian cancer. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  A. Houtsmuller,et al.  Expression of Coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers , 1999, Gene Therapy.

[7]  C. Runowicz,et al.  Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Seth,et al.  The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer , 1999, Cancer Gene Therapy.

[9]  A. Sagalowsky,et al.  Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. , 1999, Cancer research.

[10]  T. Liu,et al.  Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  A. Lissoni,et al.  Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Hasenburg,et al.  Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to chemotherapeutic agents. , 1998, Anticancer research.

[13]  L. Ellis,et al.  Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. , 1998, Cancer research.

[14]  D. Curiel,et al.  Gene therapy for ovarian carcinoma. , 1998, Seminars in oncology.

[15]  C. Contant,et al.  The efficacy of adenovirus-mediated gene therapy of ovarian cancer is enhanced by using the cytomegalovirus promoter. , 1998, Anticancer research.

[16]  A. Melcher,et al.  Personal paper: Gene therapy for cancer—managing expectations , 1997 .

[17]  W. Westra,et al.  Safety of in vivo adenovirus-mediated thymidine kinase treatment of oral cancer. , 1997, Archives of otolaryngology--head & neck surgery.

[18]  D. Brough,et al.  Adenoviral vectors for gene transfer. , 1997, Current opinion in biotechnology.

[19]  I. Verma,et al.  Gene therapy - promises, problems and prospects , 1997, Nature.

[20]  J. Wilson,et al.  The effect of promoter strength in adenoviral vectors containing herpes simplex virus thymidine kinase on cancer gene therapy in vitro and in vivo. , 1997, Cancer gene therapy.

[21]  A Gordon,et al.  Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  K. Blankenburg,et al.  Human epithelial ovarian cancer xenotransplants into nude mice can be cured by adenovirus-mediated thymidine kinase gene therapy. , 1997, Anticancer research.

[23]  D. Curiel,et al.  Adenovirus type 5 fiber knob binds to MHC class I α2 domain at the surface of human epithelial and B lymphoblastoid cells , 1997, The EMBO journal.

[24]  L. Philipson,et al.  HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Curiel,et al.  A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients. , 1997, Human gene therapy.

[26]  J. Bergelson,et al.  Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5 , 1997, Science.

[27]  J. Boyd,et al.  Adenovirus-mediated gene therapy of ovarian cancer in a mouse model. , 1996, American journal of obstetrics and gynecology.

[28]  S. Russell,et al.  Vectors for cancer gene therapy , 1996, Cancer and Metastasis Reviews.

[29]  D. Kieback,et al.  Adenovirus-mediated thymidine kinase gene transduction in human epithelial ovarian cancer cell lines followed by exposure to ganciclovir. , 1996, Anticancer research.

[30]  S. McGuire,et al.  Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. , 1996, Human gene therapy.

[31]  Edmund E. Kim,et al.  Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Gutterman,et al.  Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. , 1996, Oncogene.

[33]  J. Shellito,et al.  Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. , 1996, Human gene therapy.

[34]  G. Boivin,et al.  Anti-T cell receptor monoclonal antibody prolongs transgene expression following adenovirus-mediated in vivo gene transfer to mouse synovium. , 1996, Human gene therapy.

[35]  D. Curiel,et al.  Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  A. Gown,et al.  Long–term hepatic adenovirus–mediated gene expression in mice following CTLA4Ig administration , 1995, Nature Genetics.

[37]  A. Marrogi,et al.  The treatment of ovarian cancer with a gene modified cancer vaccine: a phase I study. , 1995, Human gene therapy.

[38]  H. Hwang,et al.  Differential sensitivity of thoracic malignant tumors to adenovirus-mediated drug sensitization gene therapy. , 1995, The Journal of thoracic and cardiovascular surgery.

[39]  H. Ertl,et al.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses , 1995, Journal of virology.

[40]  S. Woo,et al.  Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. , 1995, Cancer research.

[41]  R. Grossman,et al.  Adenovirus‐mediated gene therapy of experimental gliomas , 1994, Journal of neuroscience research.

[42]  R. Crystal,et al.  Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis , 1994, Nature Genetics.

[43]  E. Furth,et al.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[44]  R. Grossman,et al.  Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Crystal,et al.  Direct in vivo gene transfer and expression in malignant cells using adenovirus vectors. , 1994, Human gene therapy.

[46]  R. Warnick,et al.  In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. , 1993, Human gene therapy.

[47]  S. Freeman,et al.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. , 1993, Cancer research.

[48]  P. Boulanger,et al.  Involvement of cellular adhesion sequences in the attachment of adenovirus to the HeLa cell surface. , 1993, The Journal of general virology.

[49]  G. Nemerow,et al.  Integrins α v β 3 and α v β 5 promote adenovirus internalization but not virus attachment , 1993, Cell.

[50]  E. Everitt,et al.  Infectious entry pathway of adenovirus type 2 , 1991, Journal of virology.

[51]  M. Key,et al.  Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[52]  Michael C. Perry,et al.  American Society of Clinical Oncology educational book , 2003 .

[53]  M. Gore.  Treatment of relapsed epithelial ovarian cancer , 2001 .

[54]  N R Lemoine,et al.  Cancer gene therapy: hard lessons and new courses , 2000, Gene Therapy.

[55]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[56]  I. Ramzy,et al.  Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer , 2000, Cancer Gene Therapy.

[57]  D. Curiel,et al.  Targeted adenoviral vectors for cancer gene therapy. , 1998, Advances in experimental medicine and biology.

[58]  E. Venkatraman,et al.  Stage IV ovarian cancer: impact of surgical debulking. , 1997, Gynecologic oncology.

[59]  E. Atkinson,et al.  Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. , 1997, Gynecologic oncology.

[60]  M. Morgan,et al.  Effect of surgical debulking on survival in stage IV ovarian cancer. , 1997, Gynecologic oncology.

[61]  R. Crystal,et al.  Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. , 1997, Human gene therapy.

[62]  R. DeMatteo,et al.  Prolongation of adenoviral transgene expression in mouse liver by T lymphocyte subset depletion. , 1996, Gene therapy.

[63]  Z. Ram,et al.  In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. , 1993, Cancer research.